Tetra Bio-Pharma Inc. has made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market.
Tetra Bio-Pharma Inc. has made significant progress in its co-development partnership with Storz & Bickel. The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada.
Tetra Bio-Pharma Inc. announced today that Health Canada has re-classified the inhalation pipe device used in the delivery of its PPP001 cannabis drug to a Class 2 Medical Device.
Tetra Bio-Pharma Inc. announced today that it is accelerating the submission of a pre-marketing application for the registration of its cannabis drugs PPP001 and PPP005 under Directive 2001/83/EC of the European Parliament and of the Council.
Tetra Bio-Pharma Inc. is pleased to announce that it has secured a CBD supply agreement with True North Cannabis in Alberta, Canada.
Tetra Bio-Pharma Inc. is pleased to announce that Mr. Steeve Neron has joined Tetra Bio-Pharma as Vice-President, Marketing, effective August 20, 2018. He will be responsible for all Tetra Bio-Pharma and Tetra Natural Heath marketing activities.
Tetra Bio-Pharma Inc. is pleased to announce that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation. Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation.
Tetra Bio-Pharma Inc. today announced that Paradigm Capital, an independent investment banking and advisory group, based in Toronto, has initiated research coverage of Tetra Bio-Pharma.
Tetra Bio-Pharma Inc. is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain.
Tetra Bio-Pharma Inc. is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain.